Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer ; volume:25 ; number:9 ; day:17 ; month:8 ; year:2024 ; pages:1225-1237 ; date:9.2024
Current treatment options in oncology ; 25, Heft 9 (17.8.2024), 1225-1237, 9.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Bischoff, Hervé
Espié, Marc
Petit, Thierry
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-024-01252-x
- URN
-
urn:nbn:de:101:1-2412050703387.002507739797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bischoff, Hervé
- Espié, Marc
- Petit, Thierry
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer